Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

DRI Healthcare Trust (DHT_u)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.50 +0.03    +0.21%
17/05 - Closed. Currency in CAD ( Disclaimer )
  • Volume: 25,133
  • Bid/Ask: 14.50 / 14.53
  • Day's Range: 14.39 - 14.78
Type:  Equity
Market:  Canada
DRI Healthcare Trust 14.50 +0.03 +0.21%

DRI Healthcare Trust Company Profile

 
Get an in-depth profile of DRI Healthcare Trust, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

Unit

DRI Healthcare Trust (the Trust) is a Canada-based mutual fund trust. The Trust provides unitholders with differentiated exposure to the pharmaceutical and biotechnology industries through the ownership and acquisition of pharmaceutical royalties. Its products include Eylea I, Eylea II, FluMist, Natpara, Oracea, Rydapt, Spinraza, Vonjo, Xolair, Autoimmune Portfolio and others. The Trust’s therapeutic areas include ophthalmology, vaccines, oncology, endocrinology, dermatology, respiratory, rare diseases and autoimmune diseases. The Trust's products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis and Johnson & Johnson. It has over 60 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. The Trust also has a royalty interest in Zejula and Omidria. The Trust is externally managed by its manager, DRI Capital Inc.

Contact Information

Address 100 King Street West Suite 7250
PO Box 62 Toronto, M5X 1B1
Canada
Phone 416-863-1865
Fax 416-863-5161

Top Executives

Name Age Since Title
Lisa Bright - - Member of the Strategic Advisory Board - DRI Capital Inc.
Behzad Khosrowshahi - 2020 CEO & Trustee of DRI Capital Inc.
Robert A. Armitage 74 - Member of the Strategic Advisory Board - DRI Capital Inc.
Gary M. Collins 59 2021 Independent Chairman of DRI Capital Inc.
Andrea Sotak - - Chairperson of the Strategic Advisory Board - DRI Capital Inc.
Anders Lennart Tullgren 62 - Member of the Strategic Advisory Board - DRI Capital Inc.
Joshua Schafer - - Member of the Strategic Advisory Board - DRI Capital Inc.
Tamara Vrooman 54 2021 Independent Trustee of DRI Capital Inc.
Sandra Jessica Stuart 60 2021 Independent Trustee of DRI Capital Inc.
Ignacio Faus - - Member of the Strategic Advisory Board - DRI Capital Inc.
Ali G. Hedayat 47 2021 Trustee of DRI Capital Inc.
John Robert Brown 68 - Member of the Strategic Advisory Board - DRI Capital Inc.
Poonam Puri 51 2022 Independent Trustee of DRI Capital Inc.
Kevin T. Layden 62 2021 Trustee of DRI Capital Inc.
Paul Mussenden - 2021 Independent Trustee of DRI Capital Inc.
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DHT_u Comments

Write your thoughts about DRI Healthcare Trust
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email